An­oth­er AD­HD fail­ure ce­ments Ae­vi's pen­ny stock sta­tus

Ae­vi Ge­nom­ic Med­i­cine’s ge­net­ic ap­proach to treat­ing AD­HD was ex­pect­ed to as­cend its lead drug to great heights in the com­mon­ly di­ag­nosed neu­robe­hav­ioral dis­or­der, but …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER